| Compound | Target | Indication | Dose Escalation / Dose Expansion |
Clinical POC | Registrational Trial |
Marketed |
|---|---|---|---|---|---|---|
| Olverembatinib(HQP1351) | BCR-ABL | CML1, 2 |
|
|||
| CML, Ph+ ALL, SDH-deficient GIST |
|
|||||
| Lisaftoclax(APG-2575) | Bcl-2 Selective | CLL/SLL3 |
|
|||
| CLL/SLL, AML, MDS, MM4 |
|
|||||
| APG-2449 | FAK/ALK/ROS1 | NSCLC |
|
|||
| Ovarian cancer |
|
|||||
| Alrizomadlin(APG-115) | MDM2-p53 | ACC, MPNST, AML/MDS, pediatric solid tumors |
|
|||
| Pelcitoclax(APG-1252) | Bcl-2/Bcl-xL | NSCLC, SCLC, neuroendocrine tumors, NHL |
|
|||
| APG-5918 | PRC2 inhibitor | Anemia, oncology |
|
|||
| APG-3288 | BTK degrader | B-cell lymphoma |
|
|||
1 Approved November 2021 in China for TKI-resistant CML-CP and CML-AP (T315I mutation); included in China 2022 NRDL effective March 1, 2023.
2 Approved November 2023 in China for CML-CP resistant/intolerant to 1st & 2nd generation TKIs; included in China 2024 NRDL effective January 1, 2025.
3 In July 2025, Lisaftoclax was approved by NMPA in China for adult patients with CLL/SLL who have previously received at least one systemic therapy, including BTK inhibitors.
4 Registrational trials for CLL/SLL, AML and MDS; Phase 2 trials ongoing for MM.